OXB
Total Voting Rights
Oxford, UK - 03 March 2025: OXB (LSE: OXB), a global quality and innovation-led cell and
gene therapy CDMO, today announces that in accordance with the FCA's Disclosure Guidance and Transparency
Rule 5.6.1R, the Company's issued share capital as at the close of
business on 28 February 2025 consisted of 105,975,816
ordinary shares of 50 pence each ("Ordinary
Shares"). There are no Ordinary Shares held in
treasury.
Accordingly, the total number of
voting rights in OXB at the date of this notice
is 105,975,816.
The above figure 105,975,816 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in, OXB under the FCA's Disclosure Guidance and
Transparency Rules.
-Ends-
Enquiries:
OXB:
Natalie Walter, Company Secretary -
T: +44 (0) 1865 783 000 / E:
cosec@oxb.com
ICR
Healthcare:
T: +44 (0)20 3709 5700 /
E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray /
Davide Salvi
About OXB
OXB (LSE: OXB) is a
global quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell
and gene therapy, OXB has
30 years of experience in
viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing
expertise in lentivirus, adeno-associated virus (AAV), adenovirus
and other viral vector types. OXB's world-class capabilities span
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems,
analytical methods and depth of regulatory
expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the TetraVecta™ system), dual plasmid system
for AAV production, suspension and perfusion process using process
enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and
manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on LinkedIn
and YouTube.
